Log in

Co-Diagnostics Stock Forecast, Price & News

+0.51 (+3.56 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $14.82
50-Day Range
MA: $16.30
52-Week Range
Now: $14.82
Volume2.39 million shs
Average Volume7.85 million shs
Market Capitalization$416.19 million
P/E Ratio82.33
Dividend YieldN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:CODX



Sales & Book Value

Annual Sales$220,000.00
Book Value$0.10 per share


Net Income$-6,200,000.00


Market Cap$416.19 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
+0.51 (+3.56 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock price been impacted by Coronavirus?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CODX stock has increased by 12.4% and is now trading at $14.82.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Co-Diagnostics

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Co-Diagnostics

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics Inc (NASDAQ:CODX) issued its quarterly earnings results on Thursday, August, 13th. The company reported $0.43 EPS for the quarter, missing the consensus estimate of $0.59 by $0.16. The company had revenue of $24.04 million for the quarter, compared to analyst estimates of $27 million. Co-Diagnostics had a net margin of 31.42% and a return on equity of 56.17%.
View Co-Diagnostics' earnings history

What price target have analysts set for CODX?

2 brokerages have issued 12 month price targets for Co-Diagnostics' stock. Their forecasts range from $30.00 to $33.00. On average, they expect Co-Diagnostics' stock price to reach $31.50 in the next year. This suggests a possible upside of 112.6% from the stock's current price.
View analysts' price targets for Co-Diagnostics

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 7,850,000 shares, an increase of 18.0% from the August 15th total of 6,650,000 shares. Based on an average daily trading volume, of 3,850,000 shares, the days-to-cover ratio is presently 2.0 days.
View Co-Diagnostics' Short Interest

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Moderna (MRNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Ibio (IBIO), Pfizer (PFE), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.74%), Nuveen Asset Management LLC (0.79%), Barclays PLC (0.53%), Bank of New York Mellon Corp (0.36%), Advisory Services Network LLC (0.26%) and Virtu Financial LLC (0.25%). Company insiders that own Co-Diagnostics stock include Eugene Durenard and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics

Which major investors are buying Co-Diagnostics stock?

CODX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Barclays PLC, Bank of New York Mellon Corp, Virtu Financial LLC, Charles Schwab Investment Management Inc., California Public Employees Retirement System, and Swiss National Bank.
View insider buying and selling activity for Co-Diagnostics

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $14.82.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $416.19 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 39 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.